Table 2. Treatments and Outcomes After BCG.
| Characteristic or outcome | Patient data (n = 412)a |
|---|---|
| Year of BCG initiation, median (range) | 2010 (2007-2013) |
| Adequate induction therapy | 392 (95) |
| Adequate maintenance BCG therapy | 152 (37) |
| Length of BCG induction, median (IQR), d | 42 (35-288) |
| Cystectomy | 39 (9) |
| Clinical stage group, No./total No. (%) | |
| Cis with or without T1 or TaHG | 13/69 (19) |
| TaHG or T1 without Cis | 26/341 (8) |
| Progression | |
| Unknown | 2 (1) |
| No | 339 (83) |
| Yes | 71 (17) |
| Distant metastasisb | |
| Unknown | 2 (1) |
| No | 385 (94) |
| Yes | 25 (6) |
| Persistent high-risk NMIBC | |
| NA | 20 (5) |
| No | 91 (23) |
| Yes | 57 (15) |
| Unknownc | 244 (62) |
| BCG unresponsive | |
| NAd | 20 (5) |
| No | 0 |
| Yes | 26 (7) |
| Unknowne | 366 (93) |
| Complete response | |
| No | 216 (52) |
| Yes | 196 (48) |
| Recurrent high-risk NMIBC after complete response | |
| No complete response or nonadequate induction | 223 (54) |
| No | 47 (11) |
| Yes | 61 (15) |
| Unknownf | 81 (20) |
| Dead | 166 (40) |
| Death due to BC | 27 (7) |
Abbreviations: BC, bladder cancer; BCG, bacillus Calmette-Guérin; Cis, carcinoma in situ; IQR, interquartile range; NA, not available; NMIBC, non–muscle-invasive bladder cancer; TaHG, Ta high-grade.
Unless otherwise indicated, data are expressed as number (percentage) of patients. Percentages are rounded and may not equal 100.
This category represents the number with distant metastasis ever during follow-up after high-risk NMIBC.
These patients did undergo a transurethral resection of bladder tumor (TURBT) in the required time frame to determine whether the patient had persistent disease.
Twenty patients did not have the required BCG treatment to determine BCG-unresponsive disease.
These patients did undergo a TURBT in all of the required time frames to determine BCG unresponsiveness.
These patients did undergo a TURBT within 786 days of last BCG exposure to determine recurrent status.